Which of the following is true about Repaglinide?
Ans. is 'd' i.e., It should be avoided in patients with liver diseasesRef: KDT 7/e p. 2731Repaglinide:This meglitinide analogue oral hypoglycaemic is designed to normalise mealtime glucose excursions.Though not a sulfonylurea, it acts in an analogous manner by binding to SUR closure of ATP dependent K+ channels depolarisation insulin release.Repaglinide is indicated only in selected type 2 diabetics who suffer pronounced postprandial hyperglycaemia, or to supplement metformin/long-acting insulin.It should be avoided in liver disease,